Results 51 to 60 of about 10,639 (243)

Targeting Lipopolysaccharide Transport Induces Membrane Lipid Remodeling and Sensitizes Acinetobacter baumannii to Colistin Treatment

open access: yesAdvanced Science, EarlyView.
This study identifies C4 as a lead inhibitor of the Lpt system. Notably, C4 potentiates colistin activity by disrupting LPS transport and remodeling phospholipid homeostasis, revealing a functional interplay between the Lpt and Mla systems. These findings establish a mechanistic link between Lpt inhibition and membrane lipid remodeling, positioning Lpt–
Jianya Luo   +6 more
wiley   +1 more source

Resistance to polymyxins: genetic bases, epidemiology, and detection issues [PDF]

open access: yes, 2017
Polymyxins are old designed antibiotics that have recently regained significant interest as a consequence of the increasing prevalence of infections due to multidrug-resistant Gram-negative bacteria.
Endimiani, Andrea
core  

Potential toxicity of polymyxins in human lung epithelial cells [PDF]

open access: yes, 2017
Inhaled polymyxins are of considerable utility in achieving optimal exposure in the respiratory tract for the treatment of lung infections caused by multidrug-resistant Gram-negative pathogens.
Lin, Yu-Wei   +19 more
core   +1 more source

Impact of Colistin Dosing on the Incidence of Nephrotoxicity in a Tertiary Care Hospital in Saudi Arabia

open access: yesAntibiotics, 2020
Colistin therapy is associated with the development of nephrotoxicity. We examined the incidence and risk factors of nephrotoxicity associated with colistin dosing.
Reem Almutairy   +6 more
doaj   +1 more source

Colistin Use in European Livestock: Veterinary Field Data on Trends and Perspectives for Further Reduction

open access: yesVeterinary Sciences, 2022
Polymyxin E (colistin) is a medically important active substance both in human and veterinary medicine. Colistin has been used in veterinary medicine since the 1950s.
Wiebke Jansen   +5 more
doaj   +1 more source

Exploring the Roles of Tuna‐Associated Acinetobacter sp. YFT067: Implications for Host Health and Metabolism

open access: yesAnimal Research and One Health, EarlyView.
This study firstly isolated a tuna‐derived gut probiotic Acinetobacter seifertii YFT067. Dietary administration of YFT067 played significant roles in promoting growth performance, SCFAs production, lipid absorption, and metabolism of the host, indicating YFT067 as a promising probiotic candidate for enhancing tuna aquaculture productivity through ...
Ying Zou   +4 more
wiley   +1 more source

Polymyxins: To Combine or Not to Combine?

open access: yes, 2019
Polymyxins have been a mainstay for the treatment of extensively drug resistant (XDR) Gram-negative bacteria for the past two decades. Many questions regarding the clinical use of polymyxins have been answered, but whether the administration of ...
Federico Perez   +5 more
core   +1 more source

Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms

open access: yesAntibiotics
Background/Objectives: The feasibility of repurposing selective serotonin reuptake inhibitors as adjunctive antibacterial agents is an area of current investigation.
Samar A. Ahmed   +3 more
doaj   +1 more source

Polymyxins resistance: old antimicrobials, last therapeutic options

open access: yesRevista de Epidemiologia e Controle de Infecção, 2012
Polymyxins are polypeptide antimicrobials that act in the cell membranes and promote decrease of the cell wall integrity. These antimicrobials are used in the clinical practice for treatment of the multi-drug resistant Gram negative bacilli infections ...
Raquel Girardello, Ana Cristina Gales
doaj   +1 more source

Prevalence of carbapenemase-producing Klebsiella pneumonia in Gomel Region of Belarus and their sensitivity to antibiotics, antibiotic combinations, and decontaminants

open access: yesИнфекция и иммунитет, 2020
Here, we characterized in public health organizations prevalence of carbapenemase-producing Klebsiella pneumoniae, sensitivity to antimicrobial agents (AMAs), combined antimicrobial agents, and decontaminants.
D. V. Tapalski   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy